After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on ...

“I decided instead of buying an apartment on The World, I would build a ship myself. I have a background in architecture and ...